Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

118.61
+3.322.88%
Post-market: 118.610.00000.00%19:14 EDT
Volume:1.21M
Turnover:142.19M
Market Cap:17.36B
PE:10.61
High:118.77
Open:115.02
Low:114.66
Close:115.29
Loading ...

Biogen Q4 Adjusted EPS USD 3.44 VS. Ibes Estimate USD 3.35

THOMSON REUTERS
·
12 Feb

Earnings Flash (BIIB) Biogen Posts Q4 Adjusted EPS $3.44, vs. FactSet Est of $3.35

MT Newswires Live
·
12 Feb

Biogen's soft guidance and a decline in sales at MS portfolio weigh

Dow Jones
·
12 Feb

Drugmaker Biogen Forecasts 2025 Profit Below Expectations

Reuters
·
12 Feb

Biogen reports Q4 adjusted EPS $3.44, consensus $3.36

TIPRANKS
·
12 Feb

Biogen sees FY25 adjusted EPS $15.25-$16.25, consensus $16.24

TIPRANKS
·
12 Feb

Biogen Q4 2024 Adj EPS $3.44 Beats $3.35 Estimate, Sales $2.46B Beat $2.40B Estimate

Benzinga
·
12 Feb

Stock Track | Biogen Plunges 5.3% Pre-Market as 2025 Profit Outlook Disappoints, Faces Stiff Competition

Stock Track
·
12 Feb

Biogen Shares Reverse Course, Last Down 4.3% Premarket After 2025 Profit Forecast Below Estimates

THOMSON REUTERS
·
12 Feb

Biogen Shares up 1.6% Premarket After Q4 Results Beat

THOMSON REUTERS
·
12 Feb

Stock Track | Biogen Soars 8.47% Pre-market Despite Lower 2025 Profit Outlook, Boosted by R&D Deal

Stock Track
·
12 Feb

Biogen Outlook FY25 REV to Decline by a Mid-Single Digit Percentage; Ibes Estimate $9.43 Bln

THOMSON REUTERS
·
12 Feb

Biogen: Leqembi Subcutaneous Maintenance Dosing Bla Filing Accepted by FDA, Pdufa Aug 31

THOMSON REUTERS
·
12 Feb

Biogen Q4 Adj EPS $3.44 VS Ibes Estimate $3.35

THOMSON REUTERS
·
12 Feb

Biogen: to Discontinue Further Development of Biib113 in Early Alzheimer's Disease, Biib094 in Early Parkinson's Disease

THOMSON REUTERS
·
12 Feb

Biogen: to Discontinue Further Development of Biib101 in Multiple System Atrophy, Biib143 in Diabetic Peripheral Neuropathic Pain

THOMSON REUTERS
·
12 Feb

Royalty Pharma announces R&D funding collaboration with Biogen

TIPRANKS
·
12 Feb

Royalty Pharma : Litifilimab Is Currently in Phase 3 Trials for Both Sle and Cle With Results Expected Between 2026 and 2027

THOMSON REUTERS
·
12 Feb

Royalty Pharma Announces R&D Funding Collaboration With Biogen

GlobeNewswire
·
12 Feb

US STOCKS-Futures subdued in lead-up to latest inflation test

Reuters
·
12 Feb